Alpha Cognition

Alpha Cognition

Pharmaceuticals
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease, for which there are limited or no treatment options. The Company’s current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company’s commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.

$181.6M

Market Cap • 10/23/2026

2017

(9 years)

Founded

2021

(5 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

3,4

P/S

11,9

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

2,4

EPS

—

Market Cap

Market Cap

181,6M

EV

140,2M

EV/Revenue

9,2

EV/EBITDA

-4,8

EV/EBIT

-4,8

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-19,6%

Total Yield

-19,6%

Payout

0%

Retained Earnings

-112,4M

Profitability

Gross Margin

90,4%

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

27,8%

Capex/Revenue

2,1%

Capex/D&A

186%

Capex/OCF

-1%

SBC/OCF

—

% PPE

0,6%

% Goodwill

0%

ROE

—

ROIC

—

Leverage

N.D./EBITDA

1,4

Debt/Equity

0%

Current Ratio

9

Quick Ratio

7,3

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium